Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
X/T+ X-EC · 1 trial · 1 indication
Incidence of AEs/SAEs/AESIs/AEs leading to study intervention discontinuation, AEs leading to death through week 24.
| Arm | Type | Description |
|---|---|---|
| Arm A- Lecanemab + X/T + X-EC | ACTIVE_COMPARATOR | Participants will receive the active drug as well as their current Lecanemab treatment. |
| Arm B- Lecanemab + Placebo | PLACEBO_COMPARATOR | Participants will receive the non-active drug/placebo as well as their current Lecanemab treatment. |
| Name | Type | Description |
|---|---|---|
| X/T + X-EC | DRUG | Xanomeline and Trospium Chloride Capsules |
| Placebo | DRUG | Placebo |
| Lecanemab 10 mg/kg | DRUG | Participants will continue their current Lecanemab infusions while in the study receiving the study drug or placebo. |
Inclusion Criteria:1. Participants or their legally acceptable representative (LAR, see Appendix 1) must be able and willing to sign and date an IRB/IEC-approved written informed consent form ICF in accordance with regulatory, local, and institutional guidelines. This ICF must be obtained before per...
X/T+ X-EC is an investigational small molecule being developed by Bristol-Myers Squibb Company (BMY) for Alzheimer's disease. It is in Phase 2 clinical development and is being studied in participants who are currently treated with lecanemab.
X/T+ X-EC is being evaluated for use in Alzheimer's disease. The Phase 2 study is designed to assess its safety and tolerability in participants with Alzheimer's disease who are already receiving lecanemab treatment.
X/T+ X-EC is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY.
X/T+ X-EC is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 2 trial is evaluating its safety and tolerability in Alzheimer's disease.
X/T+ X-EC is being studied in one Phase 2 trial, NCT07212062, titled a study to evaluate the safety and tolerability of X/T+X-EC in participants with Alzheimer's disease who are currently treated with lecanemab. The trial is not yet recruiting and plans to enroll 60 participants.